ClinicalTrials.gg
RecruitingNCT07543120Updated Nov 16, 2026

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

A Phase 2 interventional study of QCZ484 in Hypertension (HTN), sponsored by Novartis Pharmaceuticals. Recruiting at 46 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
323
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 228 studies in Hypertension by Novartis — 5 open to participants now, 6 under way, none of them phase 3. Hypertension · Novartis.

Planned enrollment
110th of 223
323 · median 300
Started
2026
with 4 others
Phase 2
29 of 228
2 open now
Registered
225th of 228
by date

Among the 228 studies in Hypertension by Novartis, this one is the 110th largest by planned enrollment of the 223 interventional ones that give a count, is one of 5 that started in 2026, is one of 29 in phase 2, and was the 225th registered.

Hypertension

6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 228 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 557 Hypertension studies recruiting now, 264 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 138 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.

Read the detailed description

This is a single arm, multicenter, OLE study designed to evaluate long-term safety, tolerability and efficacy of QCZ484, administered SC, once Q6M, in patients with HTN, who have successfully completed treatment period in the parent studies of the QCZ484 HTN program.

Participants at sites from the parent study will be offered the option to enroll in this extension study at the Month 12 visit upon successful completion of the parent study treatment.

03

Conditions studied

  • Hypertension (HTN)

Browse trials for

Keywords

  • Hypertension
  • open-label extension study
  • QCZ484
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study.
  2. Successful completion of treatment period on QCZ484 study medication in parent study.
  3. No significant safety issue that may place participant at safety risk as determined by the Investigator.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria, may it be pre-existing or developed during the parent study, are not eligible for inclusion in this study:

  1. Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator.
  2. cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study.
  3. Permanent or persistent atrial fibrillation developed during the parent study.
  4. Clinically significant valvular heart disease developed during the parent study.
  5. Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or any time prior to enrollment.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
323 participants (estimated)

Study arms

  • Experimental
    QCZ484

    QCZ484 administered subcutaneously (SC) Q6M

    Drug: QCZ484

Interventions

  • DrugQCZ484

    QCZ484 subcutaneous injection, Q6M.

06

What researchers measure

Primary outcomes

  1. Number of participants with AEs

    Number of participants with Adverse events (AEs), including abnormal safety laboratory parameters and vital signs

    Time frame: Up to 66 months

Secondary outcomes

  1. Change in SBP and DBP assessed by ambulatory blood pressure monitoring

    Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from Baseline (parent study) and from Day 1 of the OLE and at Months 12 and so on (every 12 months) assessed by assessed by ambulatory blood pressure monitoring (ABPM) - applicable only for the subgroup of participants who had ABPM in the parent study

    Time frame: Baseline (parent study), Day 1 (OLE study) and up to month 60 (OLE study)

  2. Change in SBP and DBP assessed by office blood pressure measurement

    Change in SBP and DBP from Baseline (parent study) and from Day 1 of the OLE and at Months 6, 12 and so on (Q6M) assessed by assessed by office blood pressure measurement (OBPM)

    Time frame: Baseline (parent study), Day 1 (OLE study) and up to month 66 (OLE study)

07

Study locations

46 of 46 sites recruiting
  • SEC Clinical Research LLC
    Andalusia, Alabama 36420, United States
    Recruiting
  • Synexus Clinical Research US Inc
    Tucson, Arizona 85741, United States
    Recruiting
  • NICRs Research Center
    Garden Grove, California 92844, United States
    Recruiting
  • Downtown L A Research Center Inc
    Los Angeles, California 90017, United States
    Recruiting
  • Clinical Research of Brandon LLC
    Brandon, Florida 33511, United States
    Recruiting
  • ALL Medical Research LLC
    Cooper City, Florida 33024, United States
    Recruiting
  • National Research Institute
    Hialeah, Florida 33013, United States
    Recruiting
  • East Coast Institute for Research
    Jacksonville, Florida 32216, United States
    Recruiting
  • Entrust Clinical Research
    Miami, Florida 33176, United States
    Recruiting
  • Inpatient Research Clinical LLC
    Miami Lakes, Florida 33014, United States
    Recruiting
  • American Research Centers of FL
    Pembroke Pines, Florida 33027, United States
    Recruiting
  • Cen Exel FCR
    Tampa, Florida 33613, United States
    Recruiting
  • Cardiology Partners Clinical Research Institute
    Wellington, Florida 33449, United States
    Recruiting
  • Javara Research
    Fayetteville, Georgia 30214, United States
    Recruiting
  • Javara Research
    Fayetteville, Georgia 30214, United States
    Recruiting
  • Cedar Crosse Research Ct
    Chicago, Illinois 60607, United States
    Recruiting
    • Sanii Terry · Contactsterry@cedarcrosse.com · +1 312 431 6765#21
    • Danny Hiroshi Sugimoto · Principal investigator
  • Eagle Clinical Research
    Chicago, Illinois 60621, United States
    Recruiting
  • Synexus Clinical Research US
    Evansville, Indiana 47714, United States
    Recruiting
  • Alliance for Multispecialty Research
    Wichita, Kansas 67207, United States
    Recruiting
  • Ascension Saint Agnes Heart Care
    Baltimore, Maryland 21229, United States
    Recruiting
  • Anderson Medical Research
    Ft. Washington, Maryland 20744, United States
    Recruiting
  • Capitol Cardiology Associates
    Lanham, Maryland 20706, United States
    Recruiting
  • Oakland Medical Research Center
    Troy, Michigan 48085, United States
    Recruiting
  • Synexus Clinical Research US Inc
    Richfield, Minnesota 55432, United States
    Recruiting
  • Jefferson City Medical Group
    Jefferson City, Missouri 65109, United States
    Recruiting
  • Clin Rsrch Consult a JCCT Company
    Kansas City, Missouri 64112, United States
    Recruiting
    • Hasan Mahdi · Contacthmahdi@jcct.com · +1 816 756 1222
    • Ahmed M Awad · Principal investigator
  • CenExel HRI
    Berlin, New Jersey 08009, United States
    Recruiting
    • Danielle Brudon · Contactd.brudon@cenexel.com · +1 856 452 9901#802
    • Kyle Coupe · Principal investigator
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
    Recruiting
  • CR Services Acquisition US
    Columbus, Ohio 43213, United States
    Recruiting
  • Conrad Clinical Research
    Edmond, Oklahoma 73013, United States
    Recruiting
  • TCV Clinical Studies
    Linwood, Pennsylvania 19061, United States
    Recruiting
  • Velocity Clinical Research
    Union, South Carolina 29379, United States
    Recruiting
  • Clinical Neuroscience Solutions Inc
    Memphis, Tennessee 38119, United States
    Recruiting
  • Velocity Clinical Research Austin
    Austin, Texas 78759, United States
    Recruiting
  • Synergy Groups Medical LLC
    Missouri City, Texas 77459, United States
    Recruiting
  • Sun Research Institute
    San Antonio, Texas 78205, United States
    Recruiting
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
    Recruiting
  • Dominion Medical Associates
    Richmond, Virginia 23219, United States
    Recruiting
  • Novartis Investigative Site
    Suita, Osaka 5650853, Japan
    Recruiting
  • Novartis Investigative Site
    Chuo Ku, Tokyo 1030027, Japan
    Recruiting
  • Novartis Investigative Site
    Chuo Ku, Tokyo 1040031, Japan
    Recruiting
  • Novartis Investigative Site
    Chuo-ku, Tokyo 1030027, Japan
    Recruiting
  • Novartis Investigative Site
    Shinjuku Ku, Tokyo 1600008, Japan
    Recruiting
  • Novartis Investigative Site
    Singapore, 119074, Singapore
    Recruiting
  • Novartis Investigative Site
    Singapore, 308433, Singapore
    Recruiting
  • Novartis Investigative Site
    Singapore, 529889, Singapore
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2031, 60 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 60 months is above that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 21, 2026
StartActual
May 7, 2026
Primary completionEst.
May 7, 2031
CompletionEst.
Nov 7, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added
Show 21 added (19 United States, 1 Japan, 1 Singapore)
  • SEC Clinical Research LLC · Andalusia, United States
  • Synexus Clinical Research US Inc · Tucson, United States
  • ALL Medical Research LLC · Cooper City, United States
  • National Research Institute · Hialeah, United States
  • East Coast Institute for Research · Jacksonville, United States
  • Javara Research · Fayetteville, United States
  • Cedar Crosse Research Ct · Chicago, United States
  • Synexus Clinical Research US · Evansville, United States
  • Ascension Saint Agnes Heart Care · Baltimore, United States
  • Capitol Cardiology Associates · Lanham, United States
  • Synexus Clinical Research US Inc · Richfield, United States
  • Clin Rsrch Consult a JCCT Company · Kansas City, United States
  • CR Services Acquisition US · Columbus, United States
  • TCV Clinical Studies · Linwood, United States
  • Velocity Clinical Research · Union, United States
  • Velocity Clinical Research Austin · Austin, United States
  • Synergy Groups Medical LLC · Missouri City, United States
  • Manassas Clinical Research Center · Manassas, United States
  • Dominion Medical Associates · Richmond, United States
  • Novartis Investigative Site · Chuo Ku, Japan
  • Novartis Investigative Site · Singapore, Singapore
Nov 16, 2026
Primary completion
May 31, 2031→May 7, 2031
Nov 16, 2026
Study completion
Nov 30, 2031→Nov 7, 2031
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    21 sites added
    Show 21 added (19 United States, 1 Japan, 1 Singapore)
    • SEC Clinical Research LLC · Andalusia, United States
    • Synexus Clinical Research US Inc · Tucson, United States
    • ALL Medical Research LLC · Cooper City, United States
    • National Research Institute · Hialeah, United States
    • East Coast Institute for Research · Jacksonville, United States
    • Javara Research · Fayetteville, United States
    • Cedar Crosse Research Ct · Chicago, United States
    • Synexus Clinical Research US · Evansville, United States
    • Ascension Saint Agnes Heart Care · Baltimore, United States
    • Capitol Cardiology Associates · Lanham, United States
    • Synexus Clinical Research US Inc · Richfield, United States
    • Clin Rsrch Consult a JCCT Company · Kansas City, United States
    • CR Services Acquisition US · Columbus, United States
    • TCV Clinical Studies · Linwood, United States
    • Velocity Clinical Research · Union, United States
    • Velocity Clinical Research Austin · Austin, United States
    • Synergy Groups Medical LLC · Missouri City, United States
    • Manassas Clinical Research Center · Manassas, United States
    • Dominion Medical Associates · Richmond, United States
    • Novartis Investigative Site · Chuo Ku, Japan
    • Novartis Investigative Site · Singapore, Singapore
    Primary completion May 31, 2031→May 7, 2031
    Study completion Nov 30, 2031→Nov 7, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07543120
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
May 7, 2026
Primary completion
May 7, 2031 (estimated)
Completion
Nov 7, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QCZ484

Start the discussion